CIP2A Antibody

Western Blot: CIP2A Antibody [NB100-74663]

Western Blot: CIP2A Antibody [NB100-74663] - Characterization of CIP2A expression in a panel of normal human melanocytes (NHM) and melanoma cell lines. Cytoplasmic and nuclear expression of CIP2A in normal melanocytes, primary and metastatic melanoma cell lines assessed by immunoblot analysis. CIP2A = cancerous inhibitor of protein phosphatase 2A. Image collected and cropped by CiteAb from the following publication (https://doi.wiley.com/10.1002/cam4.425), licensed under a CC-BY license.

Immunohistochemistry: CIP2A Antibody [NB100-74663]

Immunohistochemistry: CIP2A Antibody [NB100-74663] - Section of human colon carcinoma. Antibody: Affinity purified rabbit anti-CIP2A used at a dilution of 1:100. Detection: Red-fluorescent goat anti-rabbit IgG highly cross-adsorbed Antibody used at a dilution of 1:100.

Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663]

Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663] - Section of human colon carcinoma. Antibody: Affinity purified rabbit anti-CIP2A used at a dilution of 1:250. Detection: DAB

Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663]

Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663] - Section of human ovarian carcinoma. Antibody: Affinity purified rabbit anti-CIP2A used at a dilution of 1:250. Detection: DAB

Western Blot: CIP2A Antibody [NB100-74663] -

Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-74663] -

Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-74663] -

Western Blot: CIP2A Antibody [NB100-74663] - GAS6 increases the amount of both CIP2A & p-DAPK in RSC96 cells(A) RSC96 cells were incubated with GAS6 (100 ng/ml), & immunoblotting evaluations of CIP2A & p-DAPK expression were performed. The lower panel shows the intensity during basal conditions from the scanned imaged (upper panel). (B) RSC96 cells incubated with & without GAS6 (100 ng/ml) for 30 min & analysed by immunofluorescence. (C) Immunohistochemistry images demonstrated that CIP2A expression levels were higher than sham levels at 14 days & 28 days in the cavernous nerve after BCNI. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-74663] -

Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-74663] -

Western Blot: CIP2A Antibody [NB100-74663] - GAS6 triggers p-Axl, p-DAPK & CIP2A to form a protein complex in RSC96 cells(A-B) Co-immunoprecipitation between p-Axl, p-DAPK & CIP2A with GAS6 stimulation for 30 min in RSC96 cells. Total lysate indicates 1/10 input in each experiment. The relative quantification of protein expression was normalized with respect to beta-actin expression. (C) Immunofluorescence image demonstrating co-localized CIP2A & p-Axl & co-localized p-Axl & p-DAPK (D) after GAS6 stimulation for 30 min in RSC96 cells. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-74663] -

Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663] -

Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663] - GAS6 increases the amount of both CIP2A & p-DAPK in RSC96 cells(A) RSC96 cells were incubated with GAS6 (100 ng/ml), & immunoblotting evaluations of CIP2A & p-DAPK expression were performed. The lower panel shows the intensity during basal conditions from the scanned imaged (upper panel). (B) RSC96 cells incubated with & without GAS6 (100 ng/ml) for 30 min & analysed by immunofluorescence. (C) Immunohistochemistry images demonstrated that CIP2A expression levels were higher than sham levels at 14 days & 28 days in the cavernous nerve after BCNI. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-74663] -

Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-74663] -

Western Blot: CIP2A Antibody [NB100-74663] - Characterization of CIP2A expression in a panel of normal human melanocytes (NHM) & melanoma cell lines. (A) Immunoblot analysis & (B) quantification of protein expression levels of CIP2A (C) CIP2A mRNA expression measured by qRT-PCR. NHM1 line was used as calibrator. (D) Cytoplasmic & nuclear expression of CIP2A in normal melanocytes, primary & metastatic melanoma cell lines assessed by immunoblot analysis & (E) by immunohistochemical staining. CIP2A, cancerous inhibitor of protein phosphatase 2A. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25663244), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CIP2A Antibody [NB100-74663] -

Western Blot: CIP2A Antibody [NB100-74663] - GAS6 triggered Schwann cell proliferation primarily through CIP2A & DAPK(A) RSC96 cells were transfected with either control or DAPK siRNA for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. Immunoblotting evaluations of pAxl, Axl, CIP2A, DAPK, pERK1/2, ERK1/2, pAKT, AKT, Myc & Survivin. (B) RSC96 cells were transfected with either control or CIP2A siRNA for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. Immunoblotting evaluations of pAxl, Axl, DAPK, pDAPK, pERK1/2, ERK1/2, pAKT, AKT, Myc & Survivin. (C) DAPK or CIP2A was knocked down for 48 h then RSC96 cells were incubated with GAS6 (100 ng/ml) at the indicated hours. Cell viability was analysed via the WST-1 assay. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01 vs. scramble. Image collected & cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.